Nucleoside salvage and resistance to antimetabolite anticancer agents.
作者信息
Fox M, Boyle J M, Kinsella A R
机构信息
CRC Department of Biochemical Genetics, Paterson Institute for Cancer Research, Manchester, UK.
出版信息
Br J Cancer. 1991 Sep;64(3):428-36. doi: 10.1038/bjc.1991.327.
Abstract
摘要
相似文献
1
Nucleoside salvage and resistance to antimetabolite anticancer agents.
Br J Cancer. 1991 Sep;64(3):428-36. doi: 10.1038/bjc.1991.327.
2
3
Purine nucleoside antimetabolites in development for the treatment of cancer.
Curr Opin Investig Drugs. 2004 Jun;5(6):592-6.
4
Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy.
Oncogene. 2003 Oct 20;22(47):7524-36. doi: 10.1038/sj.onc.1206952.
5
Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy.
Curr Med Chem. 2008;15(11):1072-82. doi: 10.2174/092986708784221449.
6
The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs.
Cancer Metastasis Rev. 2007 Mar;26(1):85-110. doi: 10.1007/s10555-007-9044-4.
7
Improvement of purine and pyrimidine antimetabolite-based anticancer treatment by selective suppression of mycoplasma-encoded catabolic enzymes.
Lancet Oncol. 2009 Jun;10(6):628-35. doi: 10.1016/S1470-2045(09)70037-3.
8
[The biochemistry of the cancer cell. Purine and pyrimidine metabolism].
Padiatr Padol. 1986;21(4):323-34.
9
Clinical resistance to antimetabolites.
Hematol Oncol Clin North Am. 1995 Apr;9(2):397-413.
10
In vivo metabolite- antimetabolite relationships in antitumor therapy.
Adv Enzyme Regul. 1977;16:65-77. doi: 10.1016/0065-2571(78)90067-5.
引用本文的文献
1
Discovery of Novel Pyrimidine Based Small Molecule Inhibitors as VEGFR-2 Inhibitors: Design, Synthesis, and Anti-cancer Studies.
Curr Comput Aided Drug Des. 2025;21(1):38-49. doi: 10.2174/0115734099269413231018065351.
2
Metabolomics identifies pyrimidine starvation as the mechanism of 5-aminoimidazole-4-carboxamide-1-β-riboside-induced apoptosis in multiple myeloma cells.
Mol Cancer Ther. 2013 Jul;12(7):1310-21. doi: 10.1158/1535-7163.MCT-12-1042. Epub 2013 Apr 12.
3
Optimization and evaluation of electroporation delivery of siRNA in the human leukemic CEM cell line.
Cytotechnology. 2010 Dec;62(6):497-507. doi: 10.1007/s10616-010-9309-6. Epub 2010 Oct 19.
4
Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.
Environ Mol Mutagen. 2010 Jul;51(6):659-68. doi: 10.1002/em.20603.
5
Hypoxanthine transport in human glioblastoma cells and effect on cell susceptibility to methotrexate.
Pharm Res. 2003 Nov;20(11):1804-11. doi: 10.1023/b:pham.0000003378.16802.97.
6
Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding.
Br J Cancer. 1999 Aug;80(11):1738-46. doi: 10.1038/sj.bjc.6690591.
7
Selective potentiation of lometrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage.
Br J Cancer. 1997;76(10):1300-7. doi: 10.1038/bjc.1997.552.
8
Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage.
Br J Cancer. 1997;75(7):935-45. doi: 10.1038/bjc.1997.164.
9
Differences in resistance to 5-fluorouracil as a function of cell cycle delay and not apoptosis.
Br J Cancer. 1995 Dec;72(6):1389-96. doi: 10.1038/bjc.1995.519.
10
Antibiotic C3368-A, a fungus-derived nucleoside transport inhibitor, potentiates the activity of antitumor drugs.
Cancer Chemother Pharmacol. 1995;36(2):149-54. doi: 10.1007/BF00689200.
本文引用的文献
1
2
Dependence of bone marrow cells on the liver for purine supply.
Nature. 1958 Jul 19;182(4629):191-2. doi: 10.1038/182191a0.
3
4
Uridine and cytidine metabolism following inhibition of de novo pyrimidine synthesis by pyrazofurin.
Biochim Biophys Acta. 1980 Oct 17;609(3):372-82. doi: 10.1016/0005-2787(80)90111-2.
5
Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells.
J Cell Physiol. 1980 Sep;104(3):309-19. doi: 10.1002/jcp.1041040305.
6
Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.
Cancer Res. 1980 Aug;40(8 Pt 1):2938-40.
7
Adenine, the precursor of nucleic acids in intestinal cells unable to synthesize purines de novo.
J Nutr. 1981 Oct;111(10):1816-22. doi: 10.1093/jn/111.10.1816.
8
Synergistic effects with inhibitors of de novo pyrimidine synthesis, acivicin, and N-(phosphonacetyl)-L-aspartic acid.
Cancer Res. 1981 Sep;41(9 Pt 1):3419-23.
9
Mechanism of cytotoxic action of azaguanine and thioguanine in wild-type V79 cell lines and their relative efficiency in selection of structural gene mutants.
Mutat Res. 1981 Jan;80(1):165-85. doi: 10.1016/0027-5107(81)90186-x.
10
Facilitated transport of 6-mercaptopurine and 6-thioguanine and non-mediated permeation of 8-azaguanine in Novikoff rat hepatoma cells and relationship to intracellular phosphoribosylation.
Biochim Biophys Acta. 1981 Sep 21;647(1):49-62. doi: 10.1016/0005-2736(81)90294-7.
Zotero 插件